Donepezil Hydrochloride Tablet
Product Images NDC 72162-2137

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 72162-2137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph depicting the mean change from baseline in ADAS-cog scores over 30 weeks of drug treatment. It compares Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo groups, illustrating clinical improvement or decline over time with error bars representing standard error.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A cumulative percentage curve comparing Donepezil Hydrochloride 10 mg/day and placebo in patients based on ADCS-ADL change from baseline. The x-axis shows the ADCS-ADL change values, and the y-axis represents the cumulative percentage of patients, depicting treatment response distribution between the two groups.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph comparing SIB (Severe Impairment Battery) change from baseline over 24 weeks of treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The y-axis shows SIB change from baseline, indicating clinical improvement or decline, while the x-axis represents weeks of drug treatment. The 23 mg/day dose shows a higher and sustained improvement trend compared to the 10 mg/day dose.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage graph showing change in SIB (Severe Impairment Battery) scores from baseline for Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. The x-axis represents SIB score change with negative values indicating improvement, and the y-axis represents the cumulative percentage of patients.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
A bar chart comparing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The chart shows categories ranging from markedly improved to markedly worse on the x-axis and percentage of patients on the y-axis, illustrating patient response distribution across these dose levels.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage of patients chart showing change from baseline on the x-axis and cumulative percentage on the y-axis. It compares placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg groups with lines representing each treatment. A table within the chart provides percentage responders at different ADAS-cog change points for each treatment group.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
A bar chart displaying the percentage of patients categorized by CIBIC-plus rating scores for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows levels of patient improvement or worsening, while the y-axis indicates the percentage of patients in each category.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph depicting ADAS-cog score changes from baseline over 15 weeks of drug treatment. It compares Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. The graph shows mean changes with standard error bars, indicating clinical improvement or decline relative to baseline during treatment and placebo phases.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage graph showing patient response to Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo based on change from baseline in ADAS-cog scores. The x-axis represents change from baseline ranging from -15 to 10, and the y-axis shows cumulative percentage of patients from 0 to 100%. The graph includes labeled points at -7 and -4 on the x-axis, and a table summarizing percentage of patients in each treatment group achieving ADAS-cog changes of -7, -4, and 0.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
Bar chart illustrating patient percentage distribution by CIBIC-plus Rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows CIBIC-plus Rating from Markedly Improved to Markedly Worse, and the y-axis shows Percentage of Patients, comparing the three groups' clinical response.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph depicting SIB change from baseline over 6 months of drug treatment. The x-axis shows months (0, 3, 6), and the y-axis shows mean ± standard error of SIB change from baseline ranging from -8 to 8. Two lines compare Donepezil Hydrochloride 10 mg/day and placebo, with the Donepezil group showing clinical improvement and the placebo group showing clinical decline.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage plot comparing Donepezil Hydrochloride 10 mg/day to placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients. Two curves are shown: one for Donepezil Hydrochloride (solid circles) and one for placebo (open squares). A vertical dashed line marks a reference point on the x-axis.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph comparing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment between Donepezil Hydrochloride 10 mg/day and placebo groups. The vertical axis shows clinical improvement or decline, while the horizontal axis represents months of treatment. Donepezil shows less decline compared to placebo.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride, showing its molecular arrangement including aromatic rings, methoxy groups, piperidine ring, and hydrochloride component.*
FDA Label Image

Label (Lbl721622137)

Label (Lbl721622137)
Label for Donepezil Hydrochloride Tablets USP, 10 mg strength, in a package containing 30 tablets. The product is relabeled by Bryant Ranch Prepack, Inc. and manufactured by ACI Healthcare Limited. The label includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.